HC Wainwright reaffirmed their buy rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.
Separately, Truist Financial reduced their price objective on shares of Sutro Biopharma from $18.00 to $15.00 and set a buy rating for the company in a research note on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $12.13.
Read Our Latest Analysis on STRO
Sutro Biopharma Price Performance
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.20. The business had revenue of $25.71 million during the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. On average, equities analysts anticipate that Sutro Biopharma will post -2.96 EPS for the current year.
Institutional Trading of Sutro Biopharma
A number of large investors have recently made changes to their positions in STRO. Panagora Asset Management Inc. grew its stake in shares of Sutro Biopharma by 22.4% in the fourth quarter. Panagora Asset Management Inc. now owns 451,692 shares of the company’s stock worth $1,938,000 after acquiring an additional 82,544 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $60,000. Aristides Capital LLC bought a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $217,000. Sectoral Asset Management Inc. grew its stake in shares of Sutro Biopharma by 44.3% in the fourth quarter. Sectoral Asset Management Inc. now owns 623,684 shares of the company’s stock worth $2,676,000 after acquiring an additional 191,345 shares during the period. Finally, Kynam Capital Management LP grew its stake in shares of Sutro Biopharma by 28.9% in the fourth quarter. Kynam Capital Management LP now owns 2,001,727 shares of the company’s stock worth $8,587,000 after acquiring an additional 449,052 shares during the period. 96.99% of the stock is currently owned by institutional investors.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Recommended Stories
- Five stocks we like better than Sutro Biopharma
- The Most Important Warren Buffett Stock for Investors: His Own
- How Much Can You Make in Stocks in One Month?
- Roth IRA Calculator: Calculate Your Potential Returns
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Are Dividends? Buy the Best Dividend Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.